DPDL 2014 - 4th Diabetes Partnering and Deal-Making Conference

With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?
GTC’s 4th Diabetes Partnering and Deal-Making Conference part of the Diabetes Summit 2014 scheduled for April 23-25, 2014 in Cambridge, MA, is a partnering and business development conference that gives companies an opportunity to network with high-level executives and explore potential collaborations, learn about relevant issues and deals that will affect the industry. The conference will bring together the leading experts on diabetes from both industry and academia to discuss business strategies and opportunities under the current regulatory landscape.
The Diabetes Diabetes Partnering & Deal-Making Conference includes the following sessions, panel discussions, and shared general sessions:
4th Diabetes Partnering & Deal-Making Conference:
Sessions:
I. Innovative Partnering & Licensing Strategies
II. Partnering Opportunities in Diabetes Drug Development
Panel Discussions:
I. Wining Strategies in Partnering & Deal-Making
II. Partnering with Non-Profits
III. Finding the Middle Ground in Big Pharma and Biotech Partnerships
IV. Partnering with Academia
V. Investment Opportunities in the Diabetes Space
VI. Strategies for Entry into Emerging Markets ? with focus on Arab, Latin American and Asian countries
VII. Emerging Landscape of the Insulin Market
General Session II:
Joint session with the Diabetes Drug Discovery & Development Conference
Topics:
I. Regulatory Landscape - Cardiovascular Safety
II. Biosimilar
III. Funding & Investments in Diabetes
IV. Health Economics
IV. Type 1 Diabetes: "The New Honeymoon that Last Decades" - clinical trial opportunities and the new diverse type 1 diabetic population - can we more accurately predict complications?
General Session II:
Joint session with Diabetes Summit and 2014 Stem Cell Summit
Topics:
I. Cell Therapy and Diabetes - Stem Cell Research in the Diabetes Space
II. Cell Therapy Commercialization Model
III. Close Loop System
Panel Discussions:
I. Close Loop System vs Cell Therapy
II. Acquisitions in the Diabetes Regenerative Field and the Competitive Environmen